Comparative Pharmacology
Head-to-head clinical analysis: NEXLETOL versus VASCEPA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEXLETOL versus VASCEPA.
NEXLETOL vs VASCEPA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits microsomal triglyceride transfer protein (MTP), thereby reducing the hepatic secretion of apolipoprotein B-containing lipoproteins including LDL and VLDL.
Icosapent ethyl is a prodrug that is de-esterified to the active metabolite, eicosapentaenoic acid (EPA). EPA reduces hepatic very low-density lipoprotein (VLDL) triglyceride synthesis and secretion, and increases triglyceride clearance from circulating VLDL particles.
240 mg orally once daily (two 120 mg tablets) with or without food. Do not break, crush, or chew tablets.
4 grams orally once daily (two 0.5-gram capsules twice daily or one 1-gram capsule twice daily) with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 15 to 20 hours. Steady-state reached within 2 to 4 weeks.
Terminal elimination half-life: ~89 hours (range 66-120 hours) for icosapent ethyl; steady-state achieved after 4 weeks.
Primarily hepatic metabolism followed by biliary excretion into feces. <2% excreted unchanged in urine.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Fecal excretion accounts for <5%.
Category C
Category C
Lipid-Lowering Agent
Lipid-Lowering Agent